Last reviewed · How we verify
NCT01285752
A Study of AK106-001616 in Patients With Rheumatoid Arthritis (RA)
Phase 2 trial testing AK106-001616 in Rheumatoid Arthritis in 240 participants. Completed in 1 December 2012.
1 January 2012
Quick facts
| Lead sponsor | Asahi Kasei Therapeutics Corporation |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 240 |
| Start date | 1 February 2011 |
| Primary completion | 1 January 2012 |
| Estimated completion | 1 December 2012 |
| Sites | 26 locations across Czechia, Germany, Hungary, Poland, Slovakia, Ukraine, United Kingdom |
Drugs / interventions tested
- AK106-001616 — full drug profile →
- AK106-001616 — full drug profile →
- Active comparator — full drug profile →
Conditions studied
- Rheumatoid Arthritis — all drugs for Rheumatoid Arthritis →
Sponsor
Asahi Kasei Therapeutics Corporation
Who can join
Adults 18 to 65, any sex, with Rheumatoid Arthritis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To investigate the efficacy and safety of AK106-001616 in patients with rheumatoid arthritis.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
In Silico Investigation of TATA-Binding Protein as a Therapeutic Target for Chagas Disease: Insights into FDA Drug Repositioning.
Gaona-López C, Méndez-Álvarez D, Gonzalez-Gonzalez A, Avalos-Navarro G, et al · · 2025 · PMID 40573241 · DOI 10.3390/ph18060845
Verify or expand the search:
- PubMed search for NCT01285752
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Rheumatoid Arthritis
Currently open trials in the same condition.
- NCT07433335 — A Study to Assess the Safety and Tolerability of SR-878 in Patients With Rheumatoid Arthritis · Phase 1 · recruiting
- NCT07491016 — Efficacy and Safety of Telitacicept Combined With Baricitinib for Refractory Rheumatoid Arthritis · recruiting
- NCT07171983 — A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986454 in Participants With Rheumatoid Arthritis · Phase 1 · recruiting
- NCT07246096 — Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Rel · EARLY_PHASE1 · recruiting
- NCT07363590 — A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004) · Phase 1 · recruiting
Other Asahi Kasei Therapeutics Corporation trials
Trials by the same sponsor.
- NCT05227677 — Value of Glycated Albumin in Intervention of Glycemic Control in Chinese Patients With Type 2 Diabetes · NA · completed
- NCT04483297 — First-In-Human Study of AK1320 Encapsulated Microspheres (AK1320 MS) · Phase 1 · terminated
- NCT03471988 — Clinical Study of AK1820 (Isavuconazonium Sulfate) for the Treatment of Deep Mycosis · Phase 3 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01285752 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Asahi Kasei Therapeutics Corporation
- Last refreshed: 21 July 2016
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01285752.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing